RP59500 (Quinupristin/dalfopristin): Three case reports of its use in infection due to Enterococcus faecium

J. Cassell; I. Balakrishnan; D. Samarasinghe; P. Mistry; H. G. Prentice; S. H. Gillespie

doi:10.1016/S0163-4453(98)94495-4

RP59500 (Quinupristin/dalfopristin): Three case reports of its use in infection due to Enterococcus faecium

J. Cassell
, I. Balakrishnan
, D. Samarasinghe
, P. Mistry
, H. G. Prentice
, S. H. Gillespie^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

We describe three cases of Entercoccus faecium sepsis arising in immunocompromised patients, severely ill with other conditions, who were treated with the new injectable streptogramin RP59500. There are still few reports of clinical experience with this drug. All had bacteriological resolution, with one patient recovering fully. Although two of the three patients died, this was due to underlying disease in one case and a Gram-negative superinfection in another. Quinupristin/dalfopristin therapy was not associated with significant adverse effects in any of the patients.

Original language	English
Pages (from-to)	324-327
Number of pages	4
Journal	Journal of Infection
Volume	36
Issue number	3
DOIs	https://doi.org/10.1016/S0163-4453(98)94495-4
Publication status	Published - 1 Jan 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0163-4453(98)94495-4

Handle.net

Persistent link to portal record

Cite this

@article{1c63e90fe2604a2291c3a96c0fced70f,

title = "RP59500 (Quinupristin/dalfopristin): Three case reports of its use in infection due to Enterococcus faecium",

abstract = "We describe three cases of Entercoccus faecium sepsis arising in immunocompromised patients, severely ill with other conditions, who were treated with the new injectable streptogramin RP59500. There are still few reports of clinical experience with this drug. All had bacteriological resolution, with one patient recovering fully. Although two of the three patients died, this was due to underlying disease in one case and a Gram-negative superinfection in another. Quinupristin/dalfopristin therapy was not associated with significant adverse effects in any of the patients.",

author = "J. Cassell and I. Balakrishnan and D. Samarasinghe and P. Mistry and Prentice, \{H. G.\} and Gillespie, \{S. H.\}",

year = "1998",

month = jan,

day = "1",

doi = "10.1016/S0163-4453(98)94495-4",

language = "English",

volume = "36",

pages = "324--327",

journal = "Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - RP59500 (Quinupristin/dalfopristin)

T2 - Three case reports of its use in infection due to Enterococcus faecium

AU - Cassell, J.

AU - Balakrishnan, I.

AU - Samarasinghe, D.

AU - Mistry, P.

AU - Prentice, H. G.

AU - Gillespie, S. H.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - We describe three cases of Entercoccus faecium sepsis arising in immunocompromised patients, severely ill with other conditions, who were treated with the new injectable streptogramin RP59500. There are still few reports of clinical experience with this drug. All had bacteriological resolution, with one patient recovering fully. Although two of the three patients died, this was due to underlying disease in one case and a Gram-negative superinfection in another. Quinupristin/dalfopristin therapy was not associated with significant adverse effects in any of the patients.

AB - We describe three cases of Entercoccus faecium sepsis arising in immunocompromised patients, severely ill with other conditions, who were treated with the new injectable streptogramin RP59500. There are still few reports of clinical experience with this drug. All had bacteriological resolution, with one patient recovering fully. Although two of the three patients died, this was due to underlying disease in one case and a Gram-negative superinfection in another. Quinupristin/dalfopristin therapy was not associated with significant adverse effects in any of the patients.

UR - https://www.scopus.com/pages/publications/0031864541

U2 - 10.1016/S0163-4453(98)94495-4

DO - 10.1016/S0163-4453(98)94495-4

M3 - Article

C2 - 9661946

AN - SCOPUS:0031864541

SN - 0163-4453

VL - 36

SP - 324

EP - 327

JO - Journal of Infection

JF - Journal of Infection

IS - 3

ER -

RP59500 (Quinupristin/dalfopristin): Three case reports of its use in infection due to Enterococcus faecium

Abstract

UN SDGs

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this